Milano Congressi, site of the 19th Congress of the European Hematology Association (EHA).

The 19th Congress of EHA took place June 12-15, 2014, in Milan, Italy.

Study validates drug’s efficacy in CLL/SLL

Print Friendly, PDF & Email


EHA_2014_crowd_Credit_EHA_230.jpg
Crowd at EHA 2014
Photo courtesy of EHA

Results of the phase 3 RESONATE trial suggest ibrutinib can improve response and survival rates in patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), when compared to ofatumumab. Ibrutinib conferred these benefits irrespective of baseline clinical characteristics or molecular features, including 17p deletion.... [Read Article]

Print Friendly, PDF & Email

Phase 2 results lead to breakthrough designation

Print Friendly, PDF & Email


EHA_2014_Credit_EHA_230.jpg
Attendees at EHA 2014
Photo courtesy of EHA

The US Food and Drug Administration (FDA) has granted the bispecific antibody blinatumomab breakthrough designation for the treatment of adults with relapsed or refractory B-precursor acute lymphoblastic leukemia (B-ALL). The decision was based on promising results of a phase 2 trial, which were presented at the... [Read Article]

Print Friendly, PDF & Email

Thalidomide offers short-term efficacy in HHT

Print Friendly, PDF & Email


thalidomide_bottles_240.jpg
Bottles of thalidomide

Results of a phase 2 trial suggest thalidomide can elicit solid—though not necessarily durable—responses among patients with hereditary hemorrhagic telangiectasia (HHT) suffering from severe, recurrent epistaxis. All 29 evaluable patients responded to thalidomide, with 4 achieving a complete response. Unfortunately, 11 patients relapsed at a median of 43 weeks. But re-treatment was... [Read Article]

Print Friendly, PDF & Email

Inhibitor shows promise for hematologic disorders

Print Friendly, PDF & Email


EHA_2014_attendees_Credit_EHA_230.jpg
Attendees at EHA 2014
Photo courtesy of EHA

The IDH2 inhibitor AG-221 is well-tolerated and exhibits durable clinical activity in patients with hematologic disorders, results of a phase 1 study suggest. The drug prompted responses in patients with myelodysplastic syndromes (MDS), acute myeloid leukemia (AML), and chronic myelomonocytic leukemia (CMML). Fourteen of 25 patients... [Read Article]

Print Friendly, PDF & Email

Studies confirm importance of CALR mutation in PMF

Print Friendly, PDF & Email


EHA_2104_audience_Credit_EHA_230.jpg
Audience at EHA 2014
Photo courtesy of EHA

Two new studies appear to confirm the prognostic significance of CALR mutations in patients with primary myelofibrosis (PMF). One study showed that PMF patients with mutated CALR had prolonged overall survival (OS) compared to patients with wild-type CALR. And additional subclonal mutations did not impair the... [Read Article]

Print Friendly, PDF & Email

Eltrombopag meets primary endpoint in children with ITP

Print Friendly, PDF & Email


pediatrician_and_patient_Credit_Logan_Tuttle_230.jpg
Doctor examining child
Credit: Logan Tuttle

Eltrombopag can elicit consistent platelet responses in children with immune thrombocytopenia (ITP), according to research presented at the 19th Congress of the European Hematology Association (EHA). Results of the phase 3 PETIT2 study showed that eltrombopag can significantly improve platelet counts in pediatric ITP patients, when compared to... [Read Article]

Print Friendly, PDF & Email

Approach can reduce drug-induced TLS

Print Friendly, PDF & Email


EHA_2014_session_Credit_EHA_230.jpg
Session at EHA 2014
Photo courtesy of EHA
The BCL-2 inhibitor ABT-199 may be a feasible treatment option for patients with chronic lymphocyctic leukemia/small lymphocytic lymphoma (CLL/SLL), according to research presented at the 19th Congress of the European Hematology Association (EHA). Previous results showed that ABT-199 can elicit responses in CLL/SLL patients, but... [Read Article]
Print Friendly, PDF & Email